Deutsche Bank AG Sells 65,147 Shares of Champions Oncology Inc (NASDAQ:CSBR)

Deutsche Bank AG decreased its position in Champions Oncology Inc (NASDAQ:CSBR) by 86.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,100 shares of the biotechnology company’s stock after selling 65,147 shares during the period. Deutsche Bank AG owned about 0.09% of Champions Oncology worth $78,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. BlackRock Inc. raised its holdings in Champions Oncology by 656.2% in the 3rd quarter. BlackRock Inc. now owns 123,540 shares of the biotechnology company’s stock worth $2,158,000 after purchasing an additional 107,202 shares during the period. JPMorgan Chase & Co. acquired a new position in shares of Champions Oncology in the third quarter valued at approximately $2,162,000. Vanguard Group Inc. raised its position in shares of Champions Oncology by 51.4% in the third quarter. Vanguard Group Inc. now owns 231,150 shares of the biotechnology company’s stock valued at $4,038,000 after buying an additional 78,428 shares during the last quarter. Vanguard Group Inc raised its position in shares of Champions Oncology by 51.4% in the third quarter. Vanguard Group Inc now owns 231,150 shares of the biotechnology company’s stock valued at $4,038,000 after buying an additional 78,428 shares during the last quarter. Finally, ClariVest Asset Management LLC raised its position in shares of Champions Oncology by 29.6% in the fourth quarter. ClariVest Asset Management LLC now owns 39,800 shares of the biotechnology company’s stock valued at $311,000 after buying an additional 9,100 shares during the last quarter. 52.79% of the stock is currently owned by institutional investors and hedge funds.

Separately, Zacks Investment Research upgraded shares of Champions Oncology from a “strong sell” rating to a “hold” rating in a research note on Thursday, May 2nd.

Shares of CSBR stock traded down $0.08 on Friday, hitting $7.83. The stock had a trading volume of 9,946 shares, compared to its average volume of 49,414. The stock has a market capitalization of $92.64 million, a price-to-earnings ratio of -55.93 and a beta of 1.31. The business has a 50 day simple moving average of $8.90. Champions Oncology Inc has a 52-week low of $5.71 and a 52-week high of $17.90.

About Champions Oncology

Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.

Read More: Cash Asset Ratio

Institutional Ownership by Quarter for Champions Oncology (NASDAQ:CSBR)

Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.